Introduction
Founded in 1966, Lotus is a specialty generic pharmaceutical headquartered in Taiwan with high-value, difficult-to-make portfolio covering oral oncology, CNS, CVS, women health, and anti-obesity drugs in tablets & hard/softgel capsules for global markets. It became an Alvogen Company in 2014. Externally, the primary focus of Lotus is on addressing the fast-growing oncology market and providing better access to affordable medicines. Internally, the Company aims to become the preferred partner in oncology and specialty areas. The company boasts a best in class R&D and manufacturing platform across Taiwan and Korea. Further, Lotus can reach nearly every global market with its high value pipeline through the company’s direct markets, relationship with Alvogen’s commercial units spanning over 30 countries, and through alliances with top-tier pharma companies. Currently, the Company covers more than 130 countries with its competitive portfolio.

Corporate Culture & Company Activities
We believe that businesses can gain a competitive advantage by creating a diverse and skilled workforce – fostering a culture to match. The group operates worldwide with dynamic teams of more than 100 nationalities.

Diversity enhances creativity and innovation. At Lotus, we consider ourselves a ‘next generation pharma company’, therefore we live and die on being innovative – our diverse teams, bringing their diverse perspectives, are a huge part of that.

Our unique fusion of amazing culture, carefully selected teams and respect for gender and each other has made us one of the fastest growing companies in the world. We realized that in order to get the best of talent, we need to work within the framework of a “strong, unified corporate identity” or company culture. Lotus’ “purposedriven culture” gives employees “that extra spark that enables us to create engagement and inspiration.” The Company has sponsored sports day for the elderly in Taiwan, overseas healthcare tour initiated by local doctors, BBQ day for local students from hearingimpaired schools etc. Lotus also holds cross-country and functional leadership trainings every year to build its middle management team.

Achievements and Impact
Since 2013, the Company’s revenues have grown by five times. Income before tax grew 4655% year-on-year in the first half of 2019. The Company currently employs over one thousand people around the world and has inked more than 70 licensing deals worldwide, covering more than 130 countries. Lotuspharm also launched the first generic version of expensive oncology drugs. Moving forward, the Company’s strategy revolves around a Star Map which guides it through the challenging environment. The Star Map incorporates five elements of Best Quality (manufacturing sites are approved by regulated markets authorities), Best Service (maintaining an over 95% fulfilment rate for customers, Low Cost (be a lean global organization with continuous focus on operational efficiency and cost optimization), Best People (focusing on selecting and retaining the best talent through a performance driven culture) and Best Portfolio (reviews portfolio regularly to make sure it has a balanced growth potentially from both organic and inorganic development).

Future Direction
Lotus’ purpose is to make people’s lives better by producing and distributing high quality medicines that help people live longer and healthier. Our business strategy – which involved securing the best people, the best service, the best quality products and the best portfolio – along with our Chairman, Robert Wessman’s previous experience managing a small, nearilliquid generic drug maker called Delta (later Actavis), convinced investors that a start-up could disrupt the global pharmaceutical industry.

For Lotus, our APAC region business bore fruit and became the Lotus that we know today, with a core focus on oncology medicines and complex generic pharmaceuticals, for both the fast-growing APAC and global markets.

The road to perfecting a local company and scaling up its operations to become a global player wasn’t easy. We went through several culture integrations, shifting of operational focus and eventually we strived to select 2 major areas where we think we can be a leader – oral oncology and complex formulations. We realized the need to apply a disciplined approach to investment in Lotus R&D and manufacturing – doing just a few things and doing them really well. Now we see over 70 licensing deals inked with leading global pharmaceuticals who are happy with Lotus dossiers and these global pharmaceuticals are launching Lotus products in over 130 countries.